Want to see KLRS full AI Analyst Report?
Top Page
Kalaris Therapeutics
(NASDAQ:KLRS)
Select Model
Select Model
Rating:41Neutral
Price Target:
$2.00
▼(-52.38% Downside)
Action:Reiterated
Date:10/24/26
Overall score reflects heavy financial strain from being pre-revenue with persistent losses and ongoing cash burn that is eroding equity, partially offset by low leverage. Technical signals add downside risk given a strong bearish trend and very weak momentum readings, while valuation provides limited support due to negative earnings and no dividend yield data.
Positive Factors
Low Leverage
Very low leverage limits refinancing and interest-burden risk while preserving more financial flexibility than a highly indebted clinical-stage company. This provides some capacity to prioritize research spending and manage obligations as development programs progress.
Negative Factors
No Commercial Revenue
The absence of commercial revenue means Kalaris currently lacks an internally generated revenue stream to support research, operations, or future expansion. Its financial outlook therefore remains dependent on successful development and eventual commercialization of drug candidates.
Read all positive and negative factors
Positive Factors
Negative Factors
Low Leverage
Very low leverage limits refinancing and interest-burden risk while preserving more financial flexibility than a highly indebted clinical-stage company. This provides some capacity to prioritize research spending and manage obligations as development programs progress.
Read all positive factors
Kalaris Therapeutics (KLRS) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$40.62M
Dividend YieldN/A
Average Volume (3M)82.61K
Price to Earnings (P/E)―
Beta (1Y)1.20
Revenue GrowthN/A
EPS Growth73.44%
CountryUS
Employees20
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)-2.02
Shares Outstanding23,804,981
10 Day Avg. Volume72,175
30 Day Avg. Volume82,613
Financial Highlights & Ratios
PEG Ratio0.04
Price to Book (P/B)1.63
Price to Sales (P/S)0.00
P/FCF Ratio-2.98
Enterprise Value/Market Cap0.12
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit-235.85
Enterprise Value/Ebitda-0.10
Forecast
1Y Price Target
$15.50Price Target Upside269.05% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering3
EPS Forecast (FY)-2
Revenue Forecast (FY)N/A
Kalaris Therapeutics Business Overview & Revenue Model
Company Description
Kalaris Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the development and commercialization of treatments for prevalent retinal diseases. It develops TH103, a clinical-stage anti-vascular endothelial growth factor (VEG...
How the Company Makes Money
Kalaris Therapeutics does not appear to generate recurring revenue from commercialized products; its revenue model is typical of a clinical-stage biotech. Primary funding sources are expected to include capital raising (e.g., issuing equity and/or...
Kalaris Therapeutics Financial Statement Overview
Summary
Income Statement
18
Very Negative
Balance Sheet
62
Positive
Cash Flow
24
Negative
| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit | -20.00K | -13.00K | 0.00 | 0.00 | 0.00 | -1.12M |
| EBITDA | -45.10M | -41.98M | -58.77M | -14.01M | -15.25M | -169.84M |
| Net Income | -44.26M | -43.44M | -58.77M | -14.70M | -15.48M | -171.96M |
Balance Sheet | ||||||
| Total Assets | 99.54M | 121.74M | 118.55M | 3.33M | 3.90M | 286.59M |
| Cash, Cash Equivalents and Short-Term Investments | 93.54M | 117.98M | 118.29M | 3.17M | 3.06M | 248.12M |
| Total Debt | 1.40M | 1.45M | 0.00 | 0.00 | 3.25M | 30.07M |
| Total Liabilities | 41.87M | 42.92M | 5.24M | 48.35M | 34.17M | 61.33M |
| Stockholders Equity | 57.67M | 78.81M | 113.31M | -45.02M | -30.27M | 225.27M |
Cash Flow | ||||||
| Free Cash Flow | -45.63M | -43.18M | -67.70M | -14.13M | -9.78M | -106.34M |
| Operating Cash Flow | -45.43M | -42.98M | -67.70M | -14.13M | -9.78M | -106.32M |
| Investing Cash Flow | -49.90M | -19.72M | 95.00M | 0.00 | 0.00 | 185.98M |
| Financing Cash Flow | 50.08M | 159.61M | 21.00K | 14.24M | 12.78M | 232.00K |
Kalaris Therapeutics Technical Analysis
Negative
4.20
Price Trends
3.07
Negative
3.64
Negative
5.51
Negative
Market Momentum
-0.35
Positive
25.12
Positive
6.76
Positive
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For KLRS, the sentiment is Negative. The current price of 4.2 is above the 20-day moving average (MA) of 2.28, above the 50-day MA of 3.07, and below the 200-day MA of 5.51, indicating a bearish trend. The MACD of -0.35 indicates Positive momentum. The RSI at 25.12 is Positive, neither overbought nor oversold. The STOCH value of 6.76 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for KLRS.
Kalaris Therapeutics Risk Analysis
Kalaris Therapeutics disclosed 74 risk factors in its most recent earnings report. Kalaris Therapeutics reported the most risks in the "Finance & Corporate" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
Kalaris Therapeutics Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
52 Neutral | $5.74B | -21.79 | -273.23% | ― | ― | -10.60% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
49 Neutral | $1.30B | -5.67 | -37.99% | ― | -27.15% | 23.10% | |
44 Neutral | $165.32M | -1.05 | -181.73% | ― | -64.32% | 25.83% | |
42 Neutral | $17.89M | -0.76 | -60.32% | ― | ― | 71.26% | |
41 Neutral | $40.62M | -0.92 | -71.71% | ― | ― | 73.44% | |
38 Underperform | $78.41M | -1.62 | -94.14% | ― | -0.11% | -13.99% |
* Healthcare Sector Average
KLRS
Kalaris Therapeutics
2.01
-2.86
-58.73%
CHRS
Coherus Biosciences
1.16
-0.57
-32.95%
NKTR
Nektar Therapeutics
38.55
-21.08
-35.35%
CLLS
Cellectis SA
1.26
-2.37
-65.29%
MCRB
Seres Therapeutics
1.79
-15.10
-89.40%
KOD
Kodiak Sciences
97.04
78.11
412.63%
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.